Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study

Key Points

• Lenalidomide treatment shows varying safety profiles across patients with myelodysplastic syndromes, suggesting careful monitoring is needed.
• Key evidence reveals significant variations in safety outcomes based on treatment protocols and patient characteristics.
• The observational multi-registry approach across Europe provides a comprehensive view of treatment patterns and safety.
• Findings underscore the necessity for ongoing evaluation of treatment practices and safety measures in myelodysplastic syndromes.

Abstract